210 related articles for article (PubMed ID: 32623649)
1. Is there a relationship between serum omentin level and acute phase response in patients with familial Mediterranean fever?
Can Sandikci S; Omma A; Yucel C; Omma T
Clin Rheumatol; 2021 Feb; 40(2):669-674. PubMed ID: 32623649
[TBL] [Abstract][Full Text] [Related]
2. The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods.
Çakan M; Karadağ ŞG; Tanatar A; Sönmez HE; Ayaz NA
J Clin Rheumatol; 2021 Jan; 27(1):1-4. PubMed ID: 31524848
[TBL] [Abstract][Full Text] [Related]
3. Can the Thiol/Disulfide Imbalance Be a Predictor of Colchicine Resistance in Familial Mediterranean Fever?
Omma A; Sandikci SC; Kücüksahin O; Alisik M; Erel O
J Korean Med Sci; 2017 Oct; 32(10):1588-1594. PubMed ID: 28875601
[TBL] [Abstract][Full Text] [Related]
4. Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections.
Çakan M; Aktay Ayaz N; Keskindemirci G; Karadağ ŞG; Tanatar A; Sönmez HE
Clin Rheumatol; 2020 Jan; 39(1):249-253. PubMed ID: 31485845
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of S100A12 protein levels in children with familial Mediterranean fever.
Türkmenoğlu Y; Güney E; Bezen D; İrdem A; Ertürk B; Dursun H
Turk J Med Sci; 2021 Jun; 51(3):1396-1405. PubMed ID: 33576586
[TBL] [Abstract][Full Text] [Related]
6. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.
Duzova A; Bakkaloglu A; Besbas N; Topaloglu R; Ozen S; Ozaltin F; Bassoy Y; Yilmaz E
Clin Exp Rheumatol; 2003; 21(4):509-14. PubMed ID: 12942707
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of hearing in pediatric familial Mediterranean fever patients during attack period and attack-free period.
Salimov A; Akyol U; Cildir B; Batu ED; Ozen S
Int J Pediatr Otorhinolaryngol; 2019 Apr; 119():185-192. PubMed ID: 30743166
[TBL] [Abstract][Full Text] [Related]
8. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic validity of colchicine in patients with Familial Mediterranean fever.
Ozaltin F; Bilginer Y; Gülhan B; Bajin I; Erdogan O; Hayran M; Yılmaz E; Ozen S
Clin Rheumatol; 2014 Jul; 33(7):969-74. PubMed ID: 24740462
[TBL] [Abstract][Full Text] [Related]
10. The remarkable characteristics of the children with colchicine-resistant familial Mediterranean fever in Turkey.
Sahin N; Ozdemir Cicek S; Pac Kisaarslan A; Poyrazoglu MH; Gunduz Z; Dusunsel R
Mod Rheumatol; 2022 Jan; 32(1):177-185. PubMed ID: 33775204
[TBL] [Abstract][Full Text] [Related]
11. Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
Omma A; Armaǧan B; Güven SC; Sandıkçı SC; Çolak S; Yücel Ç; Küçükşahin O; Erden A
Front Pediatr; 2021; 9():788864. PubMed ID: 34912764
[No Abstract] [Full Text] [Related]
12. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
[TBL] [Abstract][Full Text] [Related]
13. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum interleukin-1beta levels and acute phase response proteins in patients with familial Mediterranean fever.
Yildirim K; Uzkeser H; Keles M; Karatay S; Kiziltunc A; Kaya MD; Yildirim A
Biochem Med (Zagreb); 2012; 22(1):109-13. PubMed ID: 22384525
[TBL] [Abstract][Full Text] [Related]
15. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of anti-interleukin-1 therapy on subclinical inflammation parameters during the attack-free period in familial Mediterranean fever patients: A case-control study.
Atalar E; Doğan İ; Gök K; Güven SC; Maraş Y; Ceylan GG; Erten S
Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161616
[TBL] [Abstract][Full Text] [Related]
17. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever.
Kiraz S; Ertenli I; Arici M; Calgüneri M; Haznedaroglu I; Celik I; Pay S; Kirazli S
Clin Exp Rheumatol; 1998; 16(6):721-4. PubMed ID: 9844766
[TBL] [Abstract][Full Text] [Related]
18. Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever.
Onat AM; Oztürk MA; Ozçakar L; Ureten K; Kaymak SU; Kiraz S; Ertenli I; Calgüneri M
Tohoku J Exp Med; 2007 Jan; 211(1):9-14. PubMed ID: 17204829
[TBL] [Abstract][Full Text] [Related]
19. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF?
Terekeci HM; Oktenli C; Ozgurtas T; Nalbant S; Top C; Celik S; Tapan S; Kucukardali Y; Sanisoglu YS; Solmazgul E; Sahan B; Sayan O
J Rheumatol; 2008 Oct; 35(10):2024-9. PubMed ID: 18785307
[TBL] [Abstract][Full Text] [Related]
20. Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever.
Sari I; Karaoglu O; Can G; Akar S; Gulcu A; Birlik M; Akkoc N; Tunca M; Goktay Y; Onen F
Clin Rheumatol; 2007 Sep; 26(9):1467-73. PubMed ID: 17242867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
